XW043BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW043BA
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW043BA is a billable ICD-10-PCS procedure code for Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
XW043BA
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
Short Description
Introduce Orca-T Allo in Central Vein, Perc, New Tech 10
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyBOrca-T Allogeneic T-cell Immunotherapy
7QualifierANew Technology Group 10

Clinical Classification (CCSR)

AHRQ groups XW043BA into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E043GC — Introduce Oth Therap Subst in Central Vein, Perc

Similar Procedure Codes

Questions About XW043BA

Is XW043BA a billable code?

Yes. XW043BA is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW043BA mean?

XW043BA breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character B is the Device/Substance/Technology (Orca-T Allogeneic T-cell Immunotherapy); the 7th character A is the Qualifier (New Technology Group 10).

What MS-DRG does XW043BA group to?

On an inpatient stay, Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.